Non‐fatal serious adverse events · children with chronic asthma
Children: formoterol/fluticasone showed no clear difference in all‐cause non‐fatal serious adverse events compared with salmeterol/fluticasone (low certainty).
1 finding from 1 review
Asthma‐related non‐fatal serious adverse events · children with chronic asthma
1 finding from 1 review
Mortality (all‐cause) ‐ formoterol versus salbutamol ( · adults, chronic asthma: all‐cause mortality
1 finding from 1 review
All‐cause mortality ‐ formoterol/mometasone vs salmeterol/fluticasone · adults, chronic asthma: all‐cause mortality
Adults: formoterol/ICS showed no clear difference in all‐cause mortality ‐ formoterol/mometasone vs salmeterol/fluticasone compared with salmeterol/ICS (low certainty).
1 finding from 1 review
All‐cause mortality ‐ formoterol/fluticasone vs salmeterol/fluticasone · adults, chronic asthma: all‐cause mortality
Adults: formoterol/ICS showed no clear difference in all‐cause mortality ‐ formoterol/fluticasone vs salmeterol/fluticasone compared with salmeterol/ICS (low certainty).
1 finding from 1 review
All‐cause mortality formoterol/budesonide vs salmeterol/budesonide · adults, chronic asthma: all‐cause mortality
1 finding from 1 review
All‐cause non‐fatal serious adverse events ‐ formoterol and budesonide vs salmeterol and fluticasone · adults, chronic asthma: all‐cause mortality
Adults: formoterol/ICS showed no clear difference in all‐cause non‐fatal serious adverse events ‐ formoterol/budesonide… compared with salmeterol/ICS (moderate certainty).
1 finding from 1 review
All‐cause non‐fatal SAE ‐ Adults · adults, chronic asthma: all‐cause mortality
Adults: formoterol/ICS showed no clear difference in all‐cause non‐fatal serious adverse events ‐… compared with salmeterol/ICS (moderate certainty).
1 finding from 1 review
All‐cause non‐fatal serious adverse events ‐ formoterol/mometasone vs salmeterol/fluticasone · adults, chronic asthma: all‐cause mortality
Adults: formoterol/ICS showed no clear difference in all‐cause non‐fatal serious adverse events ‐ formoterol/mometasone… compared with salmeterol/ICS (moderate certainty).
1 finding from 1 review
All‐cause non‐fatal serious adverse events ‐ formoterol/fluticasone vs salmeterol/fluticasone · adults, chronic asthma: all‐cause mortality
Adults: formoterol/ICS showed no clear difference in all‐cause non‐fatal serious adverse events ‐ formoterol/fluticasone… compared with salmeterol/ICS (low certainty).
1 finding from 1 review
All‐cause mortality · adults, chronic asthma: all‐cause mortality
Regular formoterol and ICS showed no clear difference in all‐cause mortality compared with same‐dose ICS (moderate certainty).
1 finding from 1 review
Non‐fatal serious adverse events · adults, chronic asthma: all‐cause mortality
Regular formoterol and ICS showed no clear difference in all‐cause non‐fatal serious adverse events compared with same‐dose ICS (high certainty).
1 finding from 1 review
Asthma‐related mortality · adults, chronic asthma: all‐cause mortality
1 finding from 1 review
Asthma‐related non‐fatal serious adverse events · adults, chronic asthma: all‐cause mortality
Regular formoterol and ICS showed no clear difference in asthma‐related non‐fatal serious adverse events compared with same‐dose ICS (moderate certainty).
1 finding from 1 review
All‐cause mortality · children and adolescents with chronic asthma
1 finding from 1 review
Non‐fatal serious adverse events · children and adolescents with chronic asthma
Regular formoterol and ICS showed no clear difference in all‐cause non‐fatal serious adverse events compared with same‐dose ICS (moderate certainty).
1 finding from 1 review
Asthma‐related mortality · children and adolescents with chronic asthma
1 finding from 1 review
Asthma‐related non‐fatal serious adverse events · children and adolescents with chronic asthma
It is very uncertain whether regular formoterol and ICS changes asthma‐related non‐fatal serious adverse events compared with same‐dose ICS (very low certainty).
1 finding from 1 review
Linear growth velocity (cm/year) · children up to 18 years of age with persistent asthma
Effects of different delivery devices on growth in children with… showed no clear difference in linear growth velocity (cm/year) compared with chlorofluorocarbon‐metered dose inhaler beclomethasone (low certainty).
1 finding from 1 review
Change in height · children up to 18 years of age with persistent asthma
Effects of different delivery devices on growth in children with… may leads to higher change in height (cm) over a period of time compared with turbuhaler‐budesonide (low certainty).
1 finding from 1 review